Jump Financial’s Monte Rosa Therapeutics GLUE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.7M Buy
142,681
+107,781
+309% +$1.85M 0.01% 1109
2026
Q2
$845K Sell
34,900
-149,622
-81% -$2.83M 0.01% 1260
2026
Q1
$3.04M Buy
+184,522
New +$3.53M 0.04% 497
2025
Q1
– Sell
-154,842
Closed -$1.07M – 1754
2024
Q4
$1.07M Buy
+154,842
New +$1.16M 0.02% 731
2024
Q3
– Sell
-16,338
Closed -$61.1K – 1822
2024
Q2
$61.1K Sell
16,338
-560
-3% -$2.86K ﹤0.01% 1679
2024
Q1
$119K Buy
+16,898
New +$100K ﹤0.01% 1769
2022
Q4
– Sell
-18,200
Closed -$149K – 1741
2022
Q3
$149K Buy
+18,200
New +$167K 0.01% 1399

Other funds holding GLUE

Jump Financial's GLUE Position: Q3 2026 in Review

Jump Financial increased its Monte Rosa Therapeutics (GLUE) stake by 309% in Q3 2026, buying an estimated $1.85M and bringing the position to 142,681 shares worth $1.7M. The position accounts for 0.01% of the portfolio, ranked #1109.

Jump Financial first reported a position in GLUE in Q3 2022 and has held it in 7 quarters since. The position peaked at $3.04M in Q1 2026. 148 funds tracked by Wall St. Rank hold GLUE as of Q3 2026.

  • Jump Financial held 142,681 shares of Monte Rosa Therapeutics worth $1.7M as of Q3 2026.
  • Jump Financial bought 107,781 Monte Rosa Therapeutics shares in Q3 2026, an estimated $1.85M.
  • Monte Rosa Therapeutics made up 0.01% of Jump Financial's portfolio in Q3 2026, its #1109 holding.
  • Jump Financial first reported a position in Monte Rosa Therapeutics in Q3 2022 and has held it in 7 quarters since.
  • Jump Financial's Monte Rosa Therapeutics position peaked at $3.04M in Q1 2026.
  • 148 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2026.

Based on Jump Financial's 13F filing for Q3 2026, filed 13 Nov 2026.